Sep 26, 2023 / 05:35PM GMT
Charles Duncan - Cantor Fitzgerald - Analyst
Clene is a company that is, I think, a very interesting -- has a very interesting platform -- very novel platform. It is a company that is developing nanoparticles, if you will, for improving neurological disorder.
And it's a pleasure to introduce Mr. Rob Etherington, the Company's President and CEO. Rob is going to run through a presentation, and talk a little bit about what they're doing in the platform, and then hopefully talk about some very interesting data in ALS that we've seen recently updated, and speak to plans forward -- moving forward with that data. And so Rob, go ahead. Take it away, and I'll probably interrupt.
Rob Etherington - Clene Inc - President,CEO
Please do, Charles. Thank you. It's a pleasure to be with you today. Thank you for joining us. So after some forward looking statements that you've seen before, I'll make a number of statements that we are under no obligation to update. I'll jump straight in.
So this is a presentation that I'm gonna really try to spend focus time on
Clene Inc. at Cantor Fitzgerald Global Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers